Drug Profile
PF 055
Alternative Names: PF-055Latest Information Update: 18 Dec 2020
Price :
$50
*
At a glance
- Originator Renaissance Pharma
- Developer Viatris Inc
- Class Antiparasitics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Scabies
Most Recent Events
- 22 Mar 2017 No recent reports of development identified - Phase-II for Scabies (In adolescents, In children, In infants, In adults) in USA (Topical)
- 25 Mar 2014 Phase-II clinical trials in Scabies (In infants, children, adolescents and adults) in USA (Topical)